Roivant (NASDAQ: ROIV) holder logged $17M June sales, plans new stock sale

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) is the issuer for a notice of proposed sale of common shares under Rule 144 filed on behalf of Mayukh Sukhatme. The planned sale involves common stock acquired through an Exercise of Options Under a Registered Plan, with Morgan Stanley Smith Barney LLC listed as the broker.

In addition to the proposed sale, the filing lists prior sales of Roivant common shares by Mayukh Sukhatme during the past three months, including multiple transactions in June and August 2026 with six-figure share amounts and eight-figure total dollar proceeds. The sales are to be executed for cash on the NASDAQ market.

Key Figures

Shares proposed to be sold: 144,756 shares Shares sold 06/25/2026: 500,000 shares Aggregate sale amount 06/25/2026: $17,051,141.93 +4 more

7 metrics

Shares proposed to be sold 144,756 shares Common stock to be sold under Rule 144 with acquisition via option exercise as of 08/21/2026

Shares sold 06/25/2026 500,000 shares Common stock sale by Mayukh Sukhatme during past 3 months

Aggregate sale amount 06/25/2026 $17,051,141.93 Dollar amount for 500,000 ROIV common shares sold on 06/25/2026

Shares sold 06/26/2026 500,000 shares Common stock sale by Mayukh Sukhatme during past 3 months

Aggregate sale amount 06/26/2026 $17,039,650.00 Dollar amount for 500,000 ROIV common shares sold on 06/26/2026

Shares sold 08/17/2026 284,707 shares Common stock sale by Mayukh Sukhatme during past 3 months

Aggregate sale amount 08/17/2026 $10,320,571.81 Dollar amount for 284,707 ROIV common shares sold on 08/17/2026

Key Terms

Rule 144, Exercise of Options Under a Registered Plan, aggregated with sales, Common

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Options Under a Registered Plan financial

"Common | 08/21/2026 | Exercise of Options Under a Registered Plan | Issuer"

aggregated with sales regulatory

"sales are required by paragraph (e) of Rule 144 to be aggregated with sales"

Common financial

"Common | 08/21/2026 | Exercise of Options Under a Registered Plan"

FAQ

What does the Form 144 filing for ROIV by Mayukh Sukhatme disclose?

It discloses a proposed sale of Roivant Sciences Ltd. (ROIV) common shares under Rule 144 by Mayukh Sukhatme, with the shares to be sold for cash on NASDAQ and acquired through an Exercise of Options Under a Registered Plan.

Who is the selling security holder in this ROIV Form 144?

The selling security holder is Mayukh Sukhatme, for whose account Roivant Sciences Ltd. (ROIV) common shares are proposed to be sold under Rule 144. The notice also aggregates sales that must be reported together under the rule.

Which broker is named in the ROIV Form 144 filing?

The filing names Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as the broker for the planned Rule 144 sale of Roivant Sciences Ltd. (ROIV) common stock.

How were the ROIV shares to be sold by Mayukh Sukhatme acquired?

The shares to be sold were acquired through an Exercise of Options Under a Registered Plan, with the issuer identified as Roivant Sciences Ltd. and the consideration listed as Cash as of 08/21/2026.

What recent ROIV stock sales by Mayukh Sukhatme are listed in the Form 144?

The notice lists several past 3‑month sales of Roivant (ROIV) common stock by Mayukh Sukhatme, including transactions on 06/25/2026 and 06/26/2026 of 500,000 shares each, with aggregate dollar amounts in the $17 million range per transaction.

On which market are the ROIV shares in this Form 144 expected to trade?

The common shares referenced in the Form 144 for Roivant Sciences Ltd. (ROIV) are associated with trading on NASDAQ, with sales described as being conducted for Cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:20 PM Accepted by SEC EDGAR 08/21/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001750050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD.
SEC File Number	001-40782
Address of Issuer	7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	44 207 400 3347
Name of Person for Whose Account the Securities are To Be Sold	MAYUKH SUKHATME
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	144756	5280004.05	722323015	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2026	Exercise of Options Under a Registered Plan	Issuer			144756	08/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/20/2026	17519	653407.89
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/19/2026	172899	6426356.82
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/18/2026	136942	5029208.64
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/17/2026	284707	10320571.81
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	08/14/2026	243177	8809767.72
MAYUKH SUKHATME 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/26/2026	500000	17039650.00
Mayukh Sukhatme 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/25/2026	500000	17051141.93

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mayukh Sukhatme
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)